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a b s t r a c t 
Objective: Fluoropyrimidine treatment can be optimized based on dihydropyrimidine dehydrogenase 
(DPD) activity. DPD dysfunction leads to increased exposure to active metabolites, which can result in 
severe or even fatal toxicity. 
Methods: We provide an overview of 8 years of DPD diagnostic testing (n = 1194). 
Results: Within the study period, our diagnostic test evolved from a single-enzyme measurement using 
ﬁrst a radiochemical and then a nonradiochemical assay by ultra HPLC-MS in peripheral blood mononu- 
clear cells with uracil, to a combined enzymatic and genetic test (ie, polymerase chain reaction) followed 
by Sanger sequence analysis of 4 variants of the DPYD gene (ie, DPYD ∗2A , DPYD ∗13, c.2846A > T, and 1129- 
5923C > G; allele frequencies 0.58%, 0.03%, 0.29%, and 1.35%, respectively). Patients who have 1 of the 4 
variants tested (n = 814) have lower enzyme activity than the overall patient group. The majority of pa- 
tients with the DPYD ∗2A variant (83%) consistently showed decreased enzyme activity. Only 24 (25.3%) of 
95 patients (tested for 4 variants) with low enzyme activity carried a variant. Complete DPYD sequenc- 
ing in a subgroup with low enzyme activity and without DPYD ∗2A variant (n = 47) revealed 10 genetic 
variants, of which 4 have not been described previously. We did not observe a strong link between DPYD 
genotype and enzyme activity. 
Conclusions: Previous studies have shown that DPD status should be determined before treatment with 
ﬂuoropyrimidine agents to prevent unnecessary side effects with possible fatal consequences. Our study 
in combination with literature shows that there is a discrepancy between the DPD enzyme activity and 
the presence of clinically relevant single nucleotide polymorphisms. At this moment, a combination of a 
genetic and enzyme test is preferable for diagnostic testing. ( Curr Ther Res Clin Exp . 2018; 79:XXX–XXX). 
© 2018 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
Introduction 
The main chemotherapeutic agents used in many types of can- 
cer, such as colorectal, gastrointestinal, and breast cancer, are the 
ﬂuoropyrimidines 5-ﬂuorouracil (5-FU), capecitabine, and tegafur. 
Treatment with these agents is not well tolerated in a subgroup 
of patients. In 20% to 40%, moderate to severe (fatal) toxicity oc- 
curs, including nausea and vomiting, diarrhea, mucositis/stomatitis, 
myelosuppression, and hand-foot syndrome. 1 The enzyme respon- 
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sible for degradation of ﬂuoropyrimidines is dihydropyrimidine 
dehydrogenase (DPD), the ﬁrst and rate-limiting enzyme of the 
pyrimidine degradation pathway. DPD dysfunction leads to an in- 
creased exposure to active metabolites, which can result in severe 
or even fatal toxicity. 2 From the literature, the estimated percent- 
age of individuals who are DPD deﬁcient is 3% to 5% in the Cau- 
casian populations. This deﬁciency can in most cases be related 
to genetic variants in the dihydropyrimidine dehydrogenase gene 
( DPYD ). 3 The DPYD gene on chromosome 1p22 has 23 exons and 
more than 100 variants have been reported in DPYD , of which 
only few have been studied in relation to decreased DPD enzyme 
activity and/or toxicity. Of the variants studied, only 3 variants 
have been reported that were consistently associated with toxic- 
ity and decreased DPD enzyme activity in patients treated with 
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Figure 1. Evolution of dihydropyrimidine dehydrogenase (DPD) diagnostic testing 
over a period of time lasting 8 years. 
a ﬂuoropyrimidine agent: DPYD ∗2A (c.1905 + 1G > A; rs3918290), 
DPYD ∗13 (c.1679T > G p.[Ile560Ser]; rs55886062), and c.2846A > T 
p.(Asp949Val); rs67376798. 1,3 , 4 Allele frequencies for these vari- 
ants are, respectively, 0.58%, 0.03%, and 0.29%. More recently, a 
meta-analysis indicated that also the 1129-5923C > G (rs75017182) 
variant (with an allele frequency of 1.35%) is a clinically relevant 
predictor for ﬂuoropyrimidine toxicity. 5 
Several methods have been described to directly or indirectly 
determine whether a patient is DPD deﬁcient. 6 Each of these 
methods has advantages and disadvantages and currently, no as- 
say is stated to be the most optimal in terms of predicting toxicity, 
sensitivity and speciﬁcity, and cost-effectiveness. In this article, we 
provide an overview of 8 years of DPD diagnostic testing, in which 
our method changed from only DPD enzyme activity measurement 
to a combination of DPD enzyme activity assessment in peripheral 
blood mononuclear cells and DPYD genotyping for 4 variants (ie, 
DPYD ∗2A, DPYD ∗13 , rs67376798, and rs75017182). 
Materials and Methods 
Patients 
A total of 1194 patients were diagnostically tested (enzyme and 
DNA level) for the presence of complete or partial DPD deﬁciency 
in 8 years. Based on the type of screening, these were divided 
into 3 groups ( Figure 1 ). Patient group 1 consisted of 256 patients, 
who were phenotypically (DPD enzyme activity) analyzed between 
2009 and 2013. Patients with decreased enzyme activity were sub- 
sequently genotyped for the DPYD ∗2A variant. Patient group 2 con- 
sisted of 132 patients who were simultaneously phenotypically 
analyzed and genotyped for the DPYD ∗2A variant. Patient group 
3 consisted of 814 patients who were simultaneously phenotypi- 
cally analyzed and genotyped for DPYD ∗2A , DPYD ∗13 , rs67376798, 
and rs75017182. The procedures were in accordance with the eth- 
ical standards of the Helsinki Declaration of 1975 (as revised in 
1983). The study was performed alongside standard diagnostic pro- 
cedures, and thus waived from institutional review board approval. 
Phenotypic DPD analysis 
In the presence of reduced nicotinamide adenine dinu- 
cleotide phosphate, DPD converts thymine and uracil into 5,6- 
dihydrothymine and 5,6-dihydrouracil, respectively. Until Decem- 
ber 2014, DPD activity was measured according to the method 
of van Kuilenburg et al. 7 All subsequent samples were mea- 
sured using a nonradiochemical method with uracil as substrate 
instead of 14 C-labelled thymine. Peripheral blood mononuclear 
cells were isolated from 10 mL EDTA-anticoagulated blood within 
24 hours after blood draw. Pellets were suspended in 200 μL 
milli-Q Merck, (Darmstadt, Germany) and cells were lysed by 
sonication for 2 minutes (microtip MS2 (Hielscher GmbH, Tel- 
tow, Germany), cycle 0.5, amplitude 80%). Cell debris was re- 
moved by centrifugation at 11,500 g for 20 minutes at 4 °C. The 
supernatant was used for the enzymatic analysis. Protein con- 
centration was determined spectrometrically using the Pierce TM 
BCA Protein Assay Kit: Thermo (Fisher Scientiﬁc, Waltham Mas- 
sachusetts). The assay mixture contained 35 mM potassium di- 
hydrogen phosphate pH 7.4, 2.5 mM magnesium chloride, 1 
mM dithiothreitol (DTT), 250 μM NADPH, 25 μM uracil, 5 μM 
internal standard, and 50 μg total protein in a ﬁnal volume 
of 100 μL. The reaction tubes were incubated at 37 ˚C for 
60 minutes using a dry heating block. The reaction was terminated 
by the addition of 25 μL ice-cold 10% perchloric acid. The sam- 
ples were placed on crushed ice for 10 minutes to obtain complete 
precipitation. After centrifugation at 11.0 0 0 g for 5 minutes at 4 ˚C, 
subsequently 10 μL supernatant and 500 μL mobile phase ammo- 
nium formate buffer was transferred into a Costar spin-X (Corn- 
ing, New York) centrifuge tube ﬁlter, 0.2 μm nylon membrane, and 
centrifuged at 11.0 0 0 g for 1 minutes at 4 ˚C. The ﬂow-through was 
transferred into a 96-well collection plate. Components were sep- 
arated using a Waters Acquity ultra-high performance liquid chro- 
matography (Waters, Etten-Leur, the Netherlands) and analyzed on 
the Waters Xevo TQ-S tandem mass spectrometer. DPD activity was 
expressed as the amount of 5,6-dihydrouracil formed per milligram 
total protein per hour. All samples were run in duplicate. Data ac- 
quisition and chromatographic analysis was performed by using 
MassLynx software (Waters, Milford, Massachusetts). The threshold 
for decreased DPD enzyme activity was determined by testing the 
enzyme activity of controls and set at a cut-off of 30% of the lower 
end of the spectrum. For more analytical information regarding the 
measurement of DPD enzyme activity we refer to the supplemen- 
tary information. 
Genetic DPYD analysis 
Total DNA was extracted from blood using the Blood L Kit 
(Macherey-Nagel GmbH & Co. KG, Düren, Germany) and the Hamil- 
ton Microlab STAR Line (Hamilton, Bonaduz, Switzerland) accord- 
ing to the protocol of the manufacturer. Speciﬁc primers with 
an additional M13-tag were used to amplify the protein cod- 
ing exons and immediate ﬂanking intronic regions of the frag- 
ments containing the DPYD c.1905 + 1G > A (rs3918290), c.1679T > G 
(rs55886062), c.2846A > T (rs67376798), and the 1129-5923C > G 
(rs75017182) variants for standard diagnostic analysis. A subset of 
the samples was screened for the entire coding region of the DPYD 
gene, including intron/exon boundaries. Primer sequences for this 
screening are provided in Supplementary Table S1 . Ampliﬁcation 
was performed in a 10 μL reaction volume using Amplitaq Gold 
360 Master Mix with 5% 360 GC Enhancer (ThermoFisher, Nieuw- 
erkerk a/d IJssel, the Netherlands), 2 pmol of each primer and 10 
ng DNA. The cycle conditions were 96 °C for 5 minutes, followed by 
35 cycles of 94 °C for 30 seconds, 60 °C for 45 seconds, and 72 °C 
for 45 seconds with a ﬁnal elongation step of 72 °C for 10 minutes. 
The resulting polymerase chain reaction products were bidirection- 
ally sequenced using the ABI Big Dye Terminator Cycle Sequencing 
Ready Reaction kit (ThermoFisher) and the ABI3730XL genetic ana- 
lyzer (ThermoFisher). The DPYD -relevant variants were determined 
using Mutation Surveyor DNA variant analysis software (SoftGenet- 
ics, State College, Pennsylvania) with genomic National Center for 
Biotechnology Information, reference sequence NM_0 0 0110.3. All 
sequences were evaluated by 2 independent laboratory experts. 
Prediction of variants of unknown signiﬁcance 
For in silico prediction we used similar methods as described 
in Offer et al 4 but in more detail and using other additional fea- 
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Table 1 
Overview of the characteristics of the patient population. 
Total (n = 1194) Group 1 (n = 254) Group 2 (n = 126) Group 3 (n = 814) P value 
Age (y) ∗ 64.9 (10.3) 64.9 (10.4) 65.2 (11.0) 64.9 (10.2) 0.93 
Male sex † 598 (50.1) 120 (47.2) 68 (54.0) 410 (50.4) 0.45 
DPD enzyme activity (nmol/mg protein/h) ∗ n.d. 9.7 (4.3) 9.9 (3.2) 15.2 (5.7) n.d. 
Patients with decreased enzyme activity † , ‡ 213 (17.8) 84 (33.1) 34 (27.0) 95 (11.7) < 0.001 
DPD = dihydropyrimidine dehydrogenase; n.d = not determined because the enzyme activity measurements are slightly different for group 1 
and 2 in comparison to group 3 due to different methods used. 
∗ Values are presented as mean (SD). 
† Values are presented as n (%). 
‡ Reference value for low enzyme activity 7.57 nmol/mg protein/h (group 1 and 2) and 8.69 nmol/mg protein/h (group 3). 
tures all integrated in 1 software application (Alamut Visual ver- 
sion 2.7; Interactive Biosoftware, Rouen, France). Alamut Visual de- 
rives information from different public databases such as those 
maintained by the National Center for Biotechnology Information 
(NCBI), The European Bioinformatics Institute, and University of 
California Santa Cruz Genomics Institute, as well as other sources, 
including the genome Aggregation Database, the Exome Sequenc- 
ing Project, the Catalogue of Somatic Mutations in Cancer, Clin- 
Var, and the Human Gene Mutation Database. Moreover, it inte- 
grates several missense variant pathogenicity prediction tools and 
algorithms such as SIFT, PolyPhen, AlignGVGD, or MutationTaster. 
Also, the potential inﬂuence on splice junctions and visualization 
of cryptic or de novo splice sites is given. Inﬂuence on splicing reg- 
ulation can also be assessed. Results of this prediction were also 
related to the enzyme activities if measured. 
Statistical Analysis 
Enzyme activities were measured with 2 different methods: 
a radiochemical enzyme activity method (n = 380) and a nonra- 
diochemical method using ultra-HPLC–MS (n = 814). The methods 
gave slightly different values, the cut-off point for decreased en- 
zyme activity for the radiochemical enzyme activity method is 
7.57 nmol/mg protein/h and for the mass spectrometry method 
8.69 nmol/mg protein/h. Differences between groups were assessed 
using Pearson χ2 test or ANOVA. Pearson correlation and χ2 tests 
were performed to identify relationships between variables. Analy- 
ses were performed using SPSS version 22.0.0.1 (IBM-SPSS Inc, Ar- 
monk, New York). 
Results 
General characteristics of the patient population 
In a period of 8 years, 1311 DPD diagnostics requests were pro- 
cessed in our center. For 117 samples, only DNA analysis was per- 
formed. Therefore, only 1194 patients were included in the com- 
parisons shown below. Data on the development of toxicities were 
not available. An increase in the number of tests requests is ob- 
served in the last years ( Supplementary Table S2 ). Within this pe- 
riod, the diagnostic approach evolved from a focus on enzyme ac- 
tivity measurement to a combined analysis of DPD enzyme activity 
and DPYD genetic testing of 4 genetic variants ( Figure 1 ). The mean 
age of the patients analyzed for DPD in the diagnostic setting was 
64.9 years and 50.1% were men ( Table 1 ). 
Enzyme activities 
Enzyme activity was measured with 2 different methods. 
The radiochemical method was replaced by a nonradiochemical 
method in December 2014. Accuracy, precision, and reproducibil- 
ity of this method was ascertained (ISO 15189 accreditation). In 
group 3, only the nonradiochemical method was used. The refer- 
ence value for low enzyme activity appeared to be slightly differ- 
ent for the radiochemical and nonradiochemical method (7.57 vs 
8.69 nmol/mg protein/h, respectively). Therefore, we analyzed both 
groups separately. The percentage of patients with decreased en- 
zyme activity is lower in the patients analyzed in group 3. This 
is in line with the transition of only screening after evidence of 
toxicity in a patient to pretreatment screening of all patients. In 
total, DPD enzyme activity was measured in 1194 patients (380 
patients measured with the radiochemical method [groups 1 and 
2] and 814 patients measured with the nonradiochemical method 
[group 3]). We observed a small but signiﬁcant correlation be- 
tween age and DPD enzyme activity in groups 1 and 2 (Pear- 
son correlation = 0.127; P = 0.043 and Pearson correlation = 0.218; 
P = 0.014, respectively). In group 3, no signiﬁcant correlation was 
observed ( P = 0.423). Sex did not inﬂuence enzyme activity. 
Enzyme activity distribution is shown for group 3, the largest 
group tested for 4 variants (measured by the nonradiochemical 
method), in Figure 2 with 1 patient (0.1%) displaying 0 activity, 94 
(11.5%) with intermediate activity (between 0 and 8.69 nmol/mg 
protein/h), and 719 (88.3%) with normal activity ( > 8.69 nmol/mg 
protein/h). 
Genetic DPYD analyses 
Standard DPYD analysis of the 4 clinically relevant variants 
(group 3) showed that only 18% of patients with a genetic vari- 
ant had decreased enzyme activity (ie, below the threshold) 
( Figure 2 ). Their mean (SD) enzyme activity was signiﬁcantly lower 
( P < 0.001) than the patients without a genetic variant (11.0 [5.0] 
and 15.7 [5.6], respectively). The correlation between the enzyme 
activity and the presence of the ∗2A variant was most clear, with 
83.3% of patients showing decreased enzyme activity ( Table 2 ). In 
group 3, we observed 95 patients with decreased enzyme activity 
and of these only 24 (25.3%) carried at least 1 of the 4 tested vari- 
ants. 
In a subgroup of patients (n = 47) derived from patient groups 
1 and 2, the entire coding region of the DPYD gene was ana- 
lyzed. The subgroup consisted of patients with a decreased en- 
zyme activity without the DPYD ∗2A variant (n = 46) who were rou- 
tinely screened at that time and 1 patient of whom only DNA 
was available. A genetic variant was identiﬁed in 11 (23.4%) pa- 
tients. In 3 patients, DPYD ∗13 was identiﬁed. One of these pa- 
tients showed an absence of enzyme activity (0 activity). In 4 
patients, rs75017182 was identiﬁed and in 1 patient rs67376798 
was identiﬁed. All patients were heterozygous for the detected 
variants. In 3 other patients, a variant of unknown signiﬁcance 
was identiﬁed: c.601A > C p.(Ser201Arg) (rs72549308), c.2279C > T 
p.(Thr760Ile), and c.2843T > C p.(Ile948Thr). 
Discussion 
This is to our knowledge the ﬁrst article presenting 8 years of 
routine DPD testing in a clinical setting. Within this period, our di- 
agnostic approach has evolved from a focus solely on enzyme ac- 
tivity measurement to a combined analysis of DPD enzyme activity 
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Figure 2. Dihydropyrimidine dehydrogenase (DPD) genotype/phenotype correlation in the diagnostic patient population screened for 4 variants. 
and DPYD genetic testing of 4 clinically relevant genetic variants. 
We observed a strong interindividual variability in DPD enzyme ac- 
tivity within different DPYD genotypes. Patients with the DPYD ∗2A 
variant showed most consistently enzyme activity below the de- 
ﬁned threshold. The genotype–phenotype correlation for the other 
variants tested was less clear. 
In line with previous publications, 5,8 we show that there is a 
weak correlation between DPD enzyme activity and the presence 
of the variants tested. With respect to this correlation, we observed 
a sensitivity of 0.25 (24 / [24 + 71]) and a speciﬁcity of 0.93 (667 
/ [667 + 52]); that is, most patients do not carry a variant as ex- 
pected and all these patients have normal DPD enzyme activity 
(ie, high speciﬁcity). However, only 25% of patients with reduced 
activity carry a variant. The majority of patients with the DPYD ∗13, 
rs67376798, or rs75017182 variants showed enzyme activity within 
the normal range. Similar results are reported for the rs67376798 
variant in functional assays, in which this variant still showed 
∼50% activity compared with controls, whereas the DPYD ∗2A vari- 
ant showed a complete absence of activity when homozygously ex- 
pressed. 9 These observations are also in line with previous studies 
in which dose reductions based on the presence of a certain vari- 
ant showed safe treatment with capecitabine 10 and are reﬂected in 
existing pharmacogenetic dosing guidelines. The Dutch Pharmaco- 
genetics Working Group recommends for DPYD ∗2A , DPYD ∗13 , and 
rs67376798 variant carriers a starting dose of 50%, 50%, and 75%, 
respectively. Guidelines from the Clinical Pharmacogenetics Imple- 
mentation Consortium (both DPWG and CPIC PGx guidelines avail- 
able at www.pharmgkb.org ) recommend starting with 50% in gen- 
eral (independent of the variant) followed by a monitored dose in- 
crease. Patients homozygous for the rs75017182 variant were found 
to still have a remaining DPD enzyme activity of 30%, 11 indicating 
that also this variant does not result in a completely dysfunctional 
enzyme. These differences are likely caused by the different effects 
of the variant on enzyme function. For DPYD ∗2A , exon 14 skipping 
due to the induced splicing defect leads to a completely nonfunc- 
tional enzyme. DPYD ∗13 is believed to lead to destabilization of a 
sensitive region of the DPD protein, 12 although the exact functional 
consequences are not clear. The rs67376798 variant is believed to 
interfere with cofactor binding or electron transport due to a struc- 
tural change in the DPD protein. The rs75017182 variant leads to 
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Table 2 
DPYD genetic variants identiﬁed in the diagnostic setting. ∗
Genetic test (n [%]) Variant (n) Mean enzyme 
activity (min-max) 
Patients with a genetic 
variant and decreased 
enzyme activity (n [%]) 
Group 1 (n = 254) 21 (8.3) DPYD ∗2A (n = 6) 4.9 (1.8–7.4) 6 (100) 
Group 2 (n = 126) 126 (100) DPYD ∗2A (n = 2) 7.5 (7.5–7.5) 2 (100) 
Group 3 (n = 814) 814 (100) DPYD ∗1/ ∗2A (n = 12) 
DPYD ∗1/ ∗13 (n = 3) 
Heterozygous rs67376798 
(n = 12) 
heterozygous rs75017182 
(n = 46) 
rs75017182/ rs67376798 
(n = 2) 
homozygous rs75017182 
(n = 1) 
5.4 (1.2–10.5) 
12.8 (9.6–18.1) 
10.8 (4.9–18.7) 
12.8 (4.5–23.3) 
4.3 (3.3–5.3) 
8.06 
10 (83.3) 
0 (0) 
3 (25) 
8 (17.4) 
2 (100) 
1 (100) 
Subgroup entire 
screen (n = 47) † 
47 (100) DPYD ∗13 (n = 3) 
rs75017182 (n = 4) 
rs67376798 (n = 1) 
c.601A > C (n = 1) 
c.2279C > T (n = 1) 
c.2843T > C (n = 1) 
3.8 (0–7.5) 
6.1 (5.0–7.0) ‡ 
7.9 
0 
4.6 
3.2 
DPYD = dihydropyrimidine dehydrogenase. 
∗ Table only includes patients for which the enzyme activity was measured. 
† All patients were heterozygous for the variants; only c.601A > C was homozygous. 
‡ Enzyme measurements were performed for 3 samples. 
a premature stop codon in exon 11 due to aberrant splicing, but 
does not result in solely the presence of mutant transcript because 
wild-type mRNA can still be present, even in persons who are ho- 
mozygous for this variant. 13 
After sequencing the entire coding region of the DPYD gene 
in patients with decreased enzyme activity without carrying the 
DPYD ∗2A variant (from group 1), 3 variants of unknown sig- 
niﬁcance were identiﬁed. The c.601A > C p.(Ser201Arg) variant 
(rs72549308) was identiﬁed homozygously in a patient without 
DPD activity. The variant was not reported in the Exome Sequenc- 
ing Project or the 10 0 0 Genomes Project, 14 whereas the Genome 
Aggregation Database browser (277,264 alleles from unrelated in- 
dividuals) showed an allele frequency of 0.0029%. In silico predic- 
tion indicated that the variant was probably damaging and ex- 
pression of the genetic variant in HEK293T/c17 cells performed 
by Offer et al 4 showed a clear decrease in enzyme activity com- 
parable to cell lines with a DPYD ∗2A variant ( < 12.5% activity). 
This explains the absence of DPD activity in the homozygous pa- 
tient (the presence of a deletion/depletion was excluded; data not 
shown). The c.2279C > T p.(Thr760Ile) variant (ie, rs112766203) was 
also classiﬁed as probably damaging by us and others and only 
present in Genome Aggregation Database with an allele frequency 
of 0.061%. Offer et al 4 showed a decrease in DPD enzyme activ- 
ity after functional analysis comparable to the clinically relevant 
rs67376798 variant ( ∼50% activity). These results indicate that the 
presence of the variant in heterozygous state can explain the de- 
creased DPD enzyme activity found in the patient. The c.2843T > C 
p.(Ile948Thr) variant was classiﬁed as probably damaging by Ala- 
mut Visual and was not present in the Exome Sequencing Project 
and 10 0 0 Genomes Project and showed an allele frequency of 
0.0 0 041% in the Genome Aggregation Database. Recently, Kuilen- 
burg et al 15 showed residual DPD activity of 30% after functional 
analysis of this variant. Based on this information, the variant 
identiﬁed in our patient may explain the observed decreased en- 
zyme activity. One patient (heterozygous DPYD ∗13 ) showed 0 en- 
zyme activity, whereas no other DPYD variants were detected by 
sequencing the entire coding region of the DPYD gene (including 
rs75017182). Moreover, no deletions or duplications were observed 
(data not shown) to explain this absence of activity. The patient 
might have a genetic variant in a regulatory region of the DPYD 
gene located outside the sequenced coding region or other non- 
genetic factors might play a role. 
Genotyping of 4 genetic variants can only explain the genetic 
background of a small part of the patients with decreased enzyme 
activity. Presence of other variants in regions of the DPYD gene that 
have not been sequenced and genetic variants in other (ie, modi- 
ﬁer) gene regions (eg, miR27a and miR27b) 5,8 that determine DPD 
enzyme activity might be the reason that we cannot explain all 
cases of a decreased enzyme activity. In addition, other (eg, envi- 
ronmental) factors determine part of DPD enzyme activity. In our 
population, we observed a weak but statistically signiﬁcant corre- 
lation with age, which is in line with a previous publication. 16 We 
could not conﬁrm a relationship between sex and DPD enzyme ac- 
tivity, 17–19 although this has been published before. 16 Several re- 
ports indicated that DPD enzyme activity is partly determined by 
circadian rhythm, 20 although this circadian expression seems to be 
abolished in patients with gastrointestinal carcinomas. 21 In addi- 
tion, it is not unlikely that comedication can inﬂuence the expres- 
sion of DPD enzyme. Studies have indicated that oxaliplatin (an of- 
ten used anticancer agent) results in a reduced DPD activity. 22,23 
This observation could not be conﬁrmed by Boisdron-Celle et al, 24 
although they did show an effect of oxaliplatin on 5-FU plasma 
clearance. In addition, the time from blood draw to processing 
of the samples is known to inﬂuence enzyme activity. Therefore, 
our laboratory ﬂow is set up in such a way that the samples are 
processed within 18 hours. Within this time frame it is expected 
that enzyme activity is stable. 25,26 In practice, our turnaround time 
from when we receive patient blood to ﬁnishing the report is max- 
imal 7 working days. Usually we have the results around 4 to 
5 working days. The referring oncologists have agreed with our 
turnaround-times because this aligns well with other procedures 
required for the treatment of these patients and does not affect 
the start of treatment or outcome compared with not testing for 
DPD deﬁciency. 
When using both the enzymatic and genetic test results to op- 
timize ﬂuoropyrimidine treatment advice, patients who show no 
detectable DPD activity should not receive treatment with ﬂuo- 
ropyrimidine agents, according to the existing guidelines, because 
of the high risk of fatal toxicity (regardless of single nucleotide 
polymorphism [SNP] status). 1 Alternatives should be considered in 
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this situation. Patients either partially deﬁcient (ie, decreased DPD 
enzyme activity) or carrying 1 of the 4 relevant SNPs are at risk 
according to the existing guidelines and may receive an adjust- 
ment of the dose accordingly. In our opinion, only focusing on 
the enzyme test would ignore patients with low-normal activity 
who could still carry another DPYD variant and thus may be at 
risk for developing toxicity. On the other hand, focusing only on 
the genotype results is not ideal because currently we only test 4 
DPYD variants, which are certainly not the only variants that may 
cause DPD deﬁciency. 27 Starting all patients on a reduced dose and 
monitoring them afterward is not a realistic option because most 
patients will not have a (partial or complete) DPD deﬁciency and 
will experience a period of undertreatment. Because each test has 
its own advantages and disadvantages, we prefer the combination 
of both the enzyme and genotype tests as the best predictor for 
the development of side effects. 
A limitation of our study is that we did not systematically col- 
lect information concerning the development of side effects related 
to ﬂuoropyrimidine treatment. Therefore it is unclear whether the 
genetic variants or the enzyme activity predicts treatment outcome 
best. Currently, a study is being performed in the Netherlands 
addressing this issue (ClinicalTrials.gov identiﬁer: NCT02324452). 
The literature indicates that genotype-guided dosing of ﬂuorouracil 
based on DPYD ∗2A results in a reduction of grade ≥ 3 toxicity 
of 45% (from 73% in DPYD ∗2A carriers with standard dose to 28% 
in DPYD ∗2A carriers with genotype-guided dosing). 28 In addition, 
for DPD enzyme activity measurements, 58% of patients with de- 
creased enzyme activity develop severe complications (eg, grade 
4 neutropenia) versus 29% of patients with normal enzyme activ- 
ity. 29 Based on our data, 76 patients (in group 3) carried a genetic 
variant, of whom 24 showed decreased activity, whereas 95 pa- 
tients showed decreased enzyme activity in total. This means that 
severe toxicity might have been prevented in ∼18% of patients. 
The evidence that DPD testing is beneﬁcial is also reﬂected in the 
increase of the number of diagnostic DPD requests. In the initial 
years of clinical DPD testing, it was expected that most patients 
who had been tested were screened after the development of side 
effects. During the last year of clinical testing for this study, we 
observed an increase in requests for DPD testing before 5-FU treat- 
ment, which includes a shift to pretreatment screening in centers 
that only performed testing after toxicity, but also hospitals that 
never requested this type of test before. It is expected that more 
and more patients will be tested before treatment because it also 
has become evident that pharmacogenetic screening is likely cost- 
effective 28 and more extended studies are underway (eg, Clinical- 
Trials.gov identiﬁers: NCT01547923 and NCT02324452). 
Conclusions 
DPD status should be determined before treatment with ﬂuo- 
ropyrimidines to prevent patients from developing possible fatal 
toxicity and to prevent unnecessary side effects. Our study in com- 
bination with the literature shows that there is a discrepancy be- 
tween DPD enzyme activity and the presence of clinically relevant 
SNPs. Therefore, in our view, a combination of a genetic and en- 
zyme test is preferable for diagnostic testing until it is clear which 
method most reliably predicts the observed side effects. 
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